Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.51 |
| ▸ | MC1R | Q01726 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MC5R | P33032 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160673 | 1.00 | MC4R (0.51) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL29327329 | 1.00 | MC4R (0.51) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL1714377 | 0.91 | MC4R (0.52) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL1342943 | 0.91 | MC4R (0.52) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL28924798 | 0.89 | DPP4 (0.52) | MC4RMC1RDRD2DRD3SIGMAR1 | |
| SCHEMBL5924116 | 0.88 | DPP4 (0.51) | DRD2DRD3SIGMAR1S1PR1S1PR5 | |
| SCHEMBL29327391 | 0.88 | MC1R (0.51) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL1920165 | 0.88 | MC1R (0.51) | MC4RMC1RDRD2DRD3MC5R | |
| SCHEMBL23924454 | 0.87 | S1PR5 (0.49) | DRD2DRD3SIGMAR1S1PR1S1PR5 | |
| SCHEMBL23924457 | 0.87 | S1PR5 (0.49) | DRD2DRD3SIGMAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC1R 5/4885DRD2 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.